Abstract: Provided is a method of bonding an operation wire used in a medical equipment. The method includes: locally heating an adjacent region of a bonding region of an operation wire to generate an oxide in the adjacent region of the operation wire; coating the bonding region and the adjacent region with flux to remove an oxide in the bonding region and the oxide in the adjacent region; inserting a bonding end portion of the operation wire into a through-hole of a coupling material; injecting a melted bonding material into between the coupling material and the operation wire to integrally bond the coupling material and the operation wire such that the oxide remaining in the adjacent region prevents wet-spreading of the bonding material.

Abstract: A compound is provided which has thyroid-stimulating hormone receptor antagonist activity and is useful for treating thyroid-related diseases. The compound relates to a 3,4-dihydroquinolin-2(1H)-one compound represented by Formula (I) or a pharmacologically acceptable salt thereof. The compound or a pharmacologically acceptable salt thereof have antagonist activity against a thyroid-stimulating hormone receptor and is useful as a therapeutic agent for thyroid-related diseases, for example, hyperthyroidism, Graves' disease, thyroid eye disease and thyroid cancer.

Abstract: Provided is a method of bonding an operation wire used in a medical equipment. The method includes: locally heating an adjacent region of a bonding region of an operation wire to generate an oxide in the adjacent region of the operation wire; coating the bonding region and the adjacent region with flux to remove an oxide in the bonding region and the oxide in the adjacent region; inserting a bonding end portion of the operation wire into a through-hole of a coupling material; injecting a melted bonding material into between the coupling material and the operation wire to integrally bond the coupling material and the operation wire such that the oxide remaining in the adjacent region prevents wet-spreading of the bonding material.

Abstract: An object of the present invention is to improve the accuracy of clustering by avoiding detection of false clusters when automatically clustering points on a scatter diagram.

Abstract: An object of the present invention is to improve the accuracy of clustering by avoiding detection of false clusters when automatically clustering points on a scatter diagram.

Abstract: The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.

Abstract: With strength of an objective lens set to first strength, a first scanned image of a sample is produced. The strength of the objective lens is set to second strength. A rotation amount difference of a charged particle beam between the case where the strength is set to the first strength and the case where the strength is set to the second strength is specified. At the second strength, with a scanner controlled such that the rotation for canceling the rotation amount difference is supplied to the charged particle beam, a second scanned image of the sample is produced. Based on a relative positional relationship between the first and second scanned images, a deflector is controlled such that positions of the first and second scanned images coincide with each other.

Abstract: The present invention aims to provide a novel compound which has CGRP receptor antagonist activity and which is useful for the treatment of various diseases mediated by CGRP receptors. That is, the present invention relates to the pyrrolidine derivatives represented by the following formula (I) or a pharmaceutically acceptable salt thereof. In the formulae, W is ring, X is a carbon atom or the like, Y1 to Y4 are carbon atoms or the like, and R1 to R7 is alkyl or the like. The compounds of the present invention or a pharmaceutically acceptable salt thereof have an excellent CGRP receptor antagonist activity, and thus are useful as agents for the treatment of various diseases mediated by CGRP receptors.

Abstract: Magnetic field strength of a converging lens is repeatedly and alternately changed between first strength and second strength. The information about a first aperture image in the case where the magnetic field strength is the first strength and the information about a second aperture image in the case where the magnetic field strength is the second strength are produced. A first movement instruction for the first and second aperture images is given based on the first information and the second information during repetitive changes of the magnetic field strength. Based on the first movement instruction, a first deflector is controlled. A second movement instruction for the first and second aperture images is given based on the first information and the second information during repetitive changes of the magnetic field strength. Based on the second movement instruction, a second deflector is controlled.

Abstract: With strength of an objective lens set to first strength, a first scanned image of a sample is produced. The strength of the objective lens is set to second strength. A rotation amount difference of a charged particle beam between the case where the strength is set to the first strength and the case where the strength is set to the second strength is specified. At the second strength, with a scanner controlled such that the rotation for canceling the rotation amount difference is supplied to the charged particle beam, a second scanned image of the sample is produced. Based on a relative positional relationship between the first and second scanned images, a deflector is controlled such that positions of the first and second scanned images coincide with each other.

Abstract: Magnetic field strength of a converging lens is repeatedly and alternately changed between first strength and second strength. The information about a first aperture image in the case where the magnetic field strength is the first strength and the information about a second aperture image in the case where the magnetic field strength is the second strength are produced. A first movement instruction for the first and second aperture images is given based on the first information and the second information during repetitive changes of the magnetic field strength. Based on the first movement instruction, a first deflector is controlled. A second movement instruction for the first and second aperture images is given based on the first information and the second information during repetitive changes of the magnetic field strength. Based on the second movement instruction, a second deflector is controlled.

Abstract: An object is to more accurately compare diagnosis indexes with each other, which are calculated from data obtained in different environments with a cardiac-function diagnostic medicine. A conversion function calculation unit acquires a first phantom Heart/Mediastinum ratio (H/M ratio) and a second phantom H/M ratio based on a phantom, the first phantom H/M ratio that is an H/M ratio of the phantom in the first imaging environment being acquired by performing, based on phantom data that is data of a first phantom image obtained by imaging the phantom in the first imaging environment and digital phantom data that is data of a digital phantom including a cardiac ROI and a mediastinum ROI, positioning of the digital phantom on the first phantom image, and by calculating based on the phantom data of the first phantom image to which the cardiac ROI and the mediastinum ROI are set; and obtains a conversion function based on the first phantom H/M ratio and the second phantom H/M ratio.

Abstract: An object is to more accurately compare diagnosis indexes with each other, which are calculated from data obtained in different environments with a cardiac-function diagnostic medicine. A conversion function calculation unit acquires a first phantom Heart/Mediastinum ratio (H/M ratio) and a second phantom H/M ratio based on a phantom, the first phantom H/M ratio that is an H/M ratio of the phantom in the first imaging environment being acquired by performing, based on phantom data that is data of a first phantom image obtained by imaging the phantom in the first imaging environment and digital phantom data that is data of a digital phantom including a cardiac ROI and a mediastinum ROI, positioning of the digital phantom on the first phantom image, and by calculating based on the phantom data of the first phantom image to which the cardiac ROI and the mediastinum ROI are set; and obtains a conversion function based on the first phantom H/M ratio and the second phantom H/M ratio.

Abstract: A luggage support hook is attached to a center tunnel immediately above a storage unit, which is provided at a rear portion of a leg shield of a saddle-type vehicle, in order to provide a degree of freedom in a manner of hooking a hanging strap of an article to be hung on the luggage support hook, and to retain luggage in a stable state during travel. The luggage support hook is formed in a substantially Y-shape, when viewed from a front side, by a base member attached to a recess portion, a plurality of first arms projecting radially from a rear end of the base member, and a second arm member projecting from a position of the rear end of the base member. The second arm member is different from the first arms.

Abstract: The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or the like; R4 is cyano, lower alkoxycarbonyl, carboxy or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Abstract: The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or the like; R4 is cyano, lower alkoxycarbonyl, carboxy or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Abstract: The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is halo-lower alkyl, lower acyl, halo-lower alkylcarbonyl, cycloalkylcarbonyl, optionally substituted arylcarbonyl, lower alkoxycarbonyl or the like; R4 is lower alkyl, halo-lower alkyl, cycloalkyl, lower alkoxy-lower alkyl or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Abstract: A luggage support hook is attached to a center tunnel immediately above a storage unit, which is provided at a rear portion of a leg shield of a saddle-type vehicle, in order to provide a degree of freedom in a manner of hooking a hanging strap of an article to be hung on the luggage support hook, and to retain luggage in a stable state during travel. The luggage support hook is formed in a substantially Y-shape, when viewed from a front side, by a base member attached to a recess portion, a plurality of first arms projecting radially from a rear end of the base member, and a second arm member projecting from a position of the rear end of the base member. The second arm member is different from the first arms.

Abstract: The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is halo-lower alkyl, lower acyl, halo-lower alkylcarbonyl, cycloalkylcarbonyl, optionally substituted arylcarbonyl, lower alkoxycarbonyl or the like; R4 is lower alkyl, halo-lower alkyl, cycloalkyl, lower alkoxy-lower alkyl or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.